University of Cambridge > > Cambridge Society for the Application of Research (CSAR) > Harnessing cancer patients’ own immune system to control disease.

Harnessing cancer patients’ own immune system to control disease.

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact John Cook.

Cancer immunotherapy is a way of treating cancers by harnessing the patient’s own immune system to kill cancer cells. One type of cancer immunotherapy called chimeric antigen receptor (CAR) T-cell therapy involves taking patients’ T-cells, retargeting them to molecules on cancer cells, stimulating cell division to generate large numbers and putting them back into the patient. For leukemias and lymphomas, CAR -T therapy targeting a molecule called CD19 represents the most promising breakthrough in the past decade with 40 – 50% of lymphoma patients with a poor prognosis having a complete and long-lasting response. However, the response rate of CD19 -CAR-T therapy in other blood cancers with a poor prognosis can be as low as 25%. In solid cancers such as pancreatic cancer, CAR -T response rates are as low as 17%.

Our work studying how T cells detect and infiltrate cancers using preclinical models has shown that L-selectin expression by cancer specific T-cells is essential to restrict the growth of solid and disseminated cancers. These studies have revealed a strategy for increasing the efficacy of T cells by enhancing expression of L-selectin. We are currently testing whether L-selectin can be used to modify CAR -T cells to broaden their use in the clinic.

This talk is part of the Cambridge Society for the Application of Research (CSAR) series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity